1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,900 | 7,150 | 13:05 | |
| 6,950 | 7,100 | 24.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY THE CHIEF EXECUTIVE OFFICER | - | HKEx | ||
| 13.07. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT MULTIPLE RESEARCH RESULTS SELECTED FOR PRESENTATION AT 2026 ESMO | - | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 10.07. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) INCLUDED IN THE PRIORITY REVIEW AND APPROVAL ... | 1 | HKEx | ||
| 01.07. | LEADS BIOLABS-B (09887): GRANT OF AWARDS PURSUANT TO THE H SHARE AWARD SCHEME | 1 | HKEx | ||
| 25.06. | LEADS BIOLABS CO., LTD.: Leads Biolabs Announces Partner Oblenio Bio's $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development | 5 | GlobeNewswire (USA) | ||
| 25.06. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PARTNER OBLENIO CLOSES OVERSUBSCRIBED US$62 MILLION SERIES B FINANCING ROUND TO ACCELERATE CLINICAL DEVELOPMENT ... | - | HKEx | ||
| 05.06. | LEADS BIOLABS-B (09887): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 05.06. | LEADS BIOLABS-B (09887): INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION | - | HKEx | ||
| 28.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION OF PHASE II CLINICAL STUDY RESULTS OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ... | 1 | HKEx | ||
| 20.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE IN THE AMOUNT OF UP TO US$50 MILLION UNDER THE ... | - | HKEx | ||
| 19.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR ADVANCED EXTRAPULMONARY ... | 1 | HKEx | ||
| 15.05. | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 15.05. | LEADS BIOLABS-B (09887): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 15.05. | LEADS BIOLABS-B (09887): POLL RESULTS OF THE ANNUAL GENERAL MEETING APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 14.05. | LEADS BIOLABS-B (09887): INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY | 2 | HKEx | ||
| 08.05. | LEADS BIOLABS-B (09887): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION AND PROPOSED IMPLEMENTATION OF H SHARE ... | - | HKEx | ||
| 06.05. | LEADS BIOLABS CO., LTD.: LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis | 1 | GlobeNewswire (USA) | ||
| 06.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 PRIORITIZED FOR CLINICAL DEVELOPMENT IN SJOGREN'S DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, AND ... | 1 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 15, 2026 | - | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 FINAL FINANCIAL REPORT; (3) 2025 ANNUAL REPORT; (4) 2025 PROFIT DISTRIBUTION ... | 2 | HKEx |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,335 | -0,66 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,680 | +0,15 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| TARSUS PHARMACEUTICALS | 58,66 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| PRAXIS PRECISION MEDICINES | 324,95 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,430 | -0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,26 | -0,01 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| DISC MEDICINE | 74,12 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,95 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,740 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 19,110 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,690 | 0,00 % | Vir Biotechnology: Abgang des Finanzchefs schickt Aktie auf Talfahrt | ||
| TANGO THERAPEUTICS | 26,630 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| EDGEWISE THERAPEUTICS | 40,790 | -0,12 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 45,700 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 21,860 | +0,97 % | Scribe Therapeutics Inc.: Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering | ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR... ► Artikel lesen |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,92 % bei einem Aktienkurs von 6,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.